Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.34 2.43 −10.67%
Market cap
$463.6M
P/E
19.9×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(36.94%) (5.10%) (5.66%) (0.03%)
Piotroski F-Score
— — 4 4
ROA
(22.66%) (3.25%) (3.82%) (0.02%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(20.99%) (2.97%) (3.23%) (0.01%)
Average Days of Receivables
8.95 4.92 2.32 4.01
Free Cash Flow per Share
(4.40) (3.67) (2.36) (2.05)
Free Cash Flow
(55.79) (41.16) (39.84) (38.57)
Capital Expenditures
(0.06) (0.07) (0.08) (0.08)
Other line items
Cash ROIC
(13.44%) (9.05%) (9.37%) (6.16%)
Accounts Receivable Turnover
59.32 134.64 287.84 173.05
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
166.28% 89.64% 91.23% 85.05%
Selling, General and Administrative Expense of Revenue
50.54% 27.12% 27.82% 26.71%
Share Based Compensation of Revenue
10.67% 6.47% 7.15% 8.90%
Interest Coverage
— — — 4.07
Operating CF/Net income
1.45 6.71 6.23 916.21
Depreciation/Fixed assets
(8.65) (10.03) (11.71) (9.23)
Capex/Depreciation
0.03 0.03 0.03 0.03
Revenue per Share
2.93 6.45 4.21 3.97
Operating CF per Share
(4.39) (3.67) (2.35) (2.04)
Capex per Share
0.00 (0.01) 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates